Bioasis Technologies Inc.
BIOAF
Get informed when a big investor buys or sells
+ FollowMarket Cap$397.07K
Close$
Share Statistics
| Market cap | $397,070.00 |
|---|---|
| Enterprise Value | $2.70 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | 1.74 |
| Outstanding Shares | 78,212,928 |
Return
| Return on Equity | 106.63% |
|---|---|
| Return on Assets | -163.11% |
| Return on Invested Capital | 175.04% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | 0.54 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 10.02 |
| Enterprise Value to EBIT | -0.84 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.91 |
| Debt to Equity | -0.91 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$231,328
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.02
Average shareholder expectationRevenue Estimate
$157,993
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioasis Technologies Inc.
4 employees
CEO: Deborah Ann Rathjen Bioasis Technologies Inc. is a developing biopharmaceutical enterprise dedicated to the discovery and advancement of treatments and diagnostic tools for various neurological conditions. Central to its strategy is the proprietary xB3 plat...